Abstract
This review article is about the development and use of immunotherapy in the evolving treatment for early-stage lung cancer, which has profoundly altered the treatment landscape. As described in this article, early trial efforts and approvals concentrated on agents for use in the adjuvant phase of treatment and then moved to the neoadjuvant setting. Seminal trials and results are described.